Extrawell Pharmaceutical Holdings (HKSE:00858) Capex-to-Operating-Income : 0.00 (As of Mar. 2024)

View and export this data going back to 1999. Start your Free Trial

What is Extrawell Pharmaceutical Holdings Capex-to-Operating-Income?

Capex-to-Operating-Income measures a company's investments in physical assets such as property, industrial buildings or equipment to its operating income.

Extrawell Pharmaceutical Holdings's Capital Expenditure for the six months ended in Mar. 2024 was HK$0.00 Mil. Its Operating Income for the six months ended in Mar. 2024 was HK$-3.30 Mil.

GuruFocus do not calculate Capex-to-Operating-Income if the Operating Income is negative.

Extrawell Pharmaceutical Holdings Capex-to-Operating-Income Historical Data

The historical data trend for Extrawell Pharmaceutical Holdings's Capex-to-Operating-Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Extrawell Pharmaceutical Holdings Capex-to-Operating-Income Chart

Extrawell Pharmaceutical Holdings Annual Data

Trend

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Capex-to-Operating-Income

Get a 7-Day Free Trial

Extrawell Pharmaceutical Holdings Semi-Annual Data
	Sep14	Mar15	Sep15	Mar16	Sep16	Mar17	Sep17	Mar18	Sep18	Mar19	Sep19	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23	Mar24
Capex-to-Operating-Income	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Extrawell Pharmaceutical Holdings's Capex-to-Operating-Income

For the Drug Manufacturers - Specialty & Generic subindustry, Extrawell Pharmaceutical Holdings's Capex-to-Operating-Income, along with its competitors' market caps and Capex-to-Operating-Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Extrawell Pharmaceutical Holdings's Capex-to-Operating-Income Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Extrawell Pharmaceutical Holdings's Capex-to-Operating-Income distribution charts can be found below:

* The bar in red indicates where Extrawell Pharmaceutical Holdings's Capex-to-Operating-Income falls into.

Extrawell Pharmaceutical Holdings Capex-to-Operating-Income Calculation

Extrawell Pharmaceutical Holdings's Capex-to-Operating-Income for the fiscal year that ended in Mar. 2024 is calculated as

Capex-to-Operating-Income	=	- Capital Expenditure	/	Operating Income
	=	- (-1.202)	/	-6.526
	=	N/A

Extrawell Pharmaceutical Holdings's Capex-to-Operating-Income for the quarter that ended in Mar. 2024 is calculated as

Capex-to-Operating-Income	=	- Capital Expenditure	/	Operating Income
	=	- (0)	/	-3.302
	=	N/A

Extrawell Pharmaceutical Holdings (HKSE:00858) Capex-to-Operating-Income Explanation

Capex-to-Operating-Income assesses how much emphasis a company is placing upon investing in capital-intensive projects. The ratio is generally a good gauge to quantify how much focus on growth a company has. Typically, smaller companies that are still growing and expanding will have a higher Capex to Operating Income Ratio, since such businesses are likely investing more in physical assets. Lower ratios could indicate that a company has reached maturity and it is no longer pursuing aggressive growth.

Extrawell Pharmaceutical Holdings Capex-to-Operating-Income Related Terms

Thank you for viewing the detailed overview of Extrawell Pharmaceutical Holdings's Capex-to-Operating-Income provided by GuruFocus.com. Please click on the following links to see related term pages.

Extrawell Pharmaceutical Holdings Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Extrawell Pharmaceutical Holdings Ltd (HKSE:00858) » Definitions » Capex-to-Operating-Income

Traded in Other Exchanges

N/A

Address

979 King’s Road, Suites 2206-08, 22nd Floor, Devon House, Taikoo Place, Quarry Bay, Hong Kong, HKG

Website

http://www.extrawell.com.hk

Extrawell Pharmaceutical Holdings Ltd is an investment holding company. The company's operating segment includes Manufacturing; Trading and Gene Development. It generates maximum revenue from the Manufacturing segment. The manufacturing segment is engaged in the development, manufacture, and sales of pharmaceutical products. Its trading segment is engaged in the marketing and distribution of imported pharmaceutical products. The gene development segment is engaged in the commercial exploitation and development of genome-related technology. Geographically, it derives a majority of its revenue from China.

Executives

Mao Yumin	2201 Interest of corporation controlled by you
Biowindow Gene Development (hong Kong) Limited	2201 Interest of corporation controlled by you
Ease Gold Investments Limited	2201 Interest of corporation controlled by you
Jnj Investments Ltd	2201 Interest of corporation controlled by you
United Gene Group Ltd	2201 Interest of corporation controlled by you
United Gene Holdings Limited	2201 Interest of corporation controlled by you
United Gene International Holdings Group Limited	2101 Beneficial owner
Xie Yi	2201 Interest of corporation controlled by you
Huang Zhenping	2101 Beneficial owner
United Gene Industry Group Limited	2101 Beneficial owner
Chen Xuhua	2202 Interest of your spouse
Cheng Yong	2201 Interest of corporation controlled by you

Extrawell Pharmaceutical Holdings Headlines

No Headlines